McKesson Corporation MCK
NYSE · United States · Distribution Services
$853.81-11.01 (-1.27%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The shares underperformed the S&P 500 in the latest session, while analysts’ consensus calls for higher earnings and revenue in the upcoming report.
Zacks points to growth across several businesses, while pricing pressure and weaker Medical-Surgical results remain risks for the distributor.
The healthcare distributor raised earnings guidance after a strong first quarter and outlined how a $2.25 billion deal will deepen its oncology platform.
AbbVie bets on pipeline diversification amid patent cliffs, while J&J's higher profitability masks litigation risks, a choice between growth ambition and defensive stability.
AbbVie pivots toward newer immunology drugs while Pfizer leans on acquisitions to offset pandemic decline, but their financial profiles and valuations tell starkly different stories.
McKesson (MCK) is back in focus after its share price dipped 1.2%, trailing the broader market, as investors weigh mixed earnings estimates against the company’s raised full-year adjusted EPS guidance and specialty-led healthcare footprint. Recent trading has been choppy for McKesson, with the share price slipping 3.95% over the past 30 days even after a 13.86% 90 day share price return and a 5.58% share price gain year to date. That near term hesitation sits against a much stronger backdrop,...
Novo Nordisk trades at a steep discount on earnings and sales, while AbbVie grapples with patent cliffs and pricing pressure, but profitability tells a different story.
AbbVie leans on legacy income and portfolio transition, while Eli Lilly rides explosive growth in weight-loss drugs, but at vastly different valuations.
IRVING, Texas, September 23, 2026--McKesson Corporation (NYSE: MCK) will release its second quarter fiscal 2027 financial results after market close on Wednesday, November 4, 2026. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results.
Since March 2026, McKesson has been in a holding pattern, floating around $872.99. The stock also fell short of the S&P 500’s 16.4% gain during that period.
AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
Alluvium Asset Management, an asset management company, released its “Conventum – Alluvium Global Fund” second-quarter 2026 investor letter. The letter can be downloaded here. The second quarter reflected a sharp shift from geopolitical uncertainty and oil market volatility to a powerful equity rally led by semiconductor companies. Despite the broader market strength, the Fund declined […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.